HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients.

AbstractAIM:
This study was designed to characterize the population pharmacokinetics of isoniazid in South African pulmonary tuberculosis patients.
METHODS:
Concentration-time measurements obtained from 235 patients receiving oral doses of isoniazid as part of routine tuberculosis chemotherapy in two clinical studies were pooled and subjected to nonlinear mixed-effects analysis.
RESULTS:
A two-compartmental model, including first-order absorption and elimination with allometric scaling, was found to describe the observed dose-exposure relationship for oral isoniazid adequately. A mixture model was used to characterize dual rates of isoniazid elimination. Estimates of apparent clearance in slow and fast eliminators were 9.70 and 21.6 l h(-1) , respectively. The proportion of fast eliminators in the population was estimated to be 13.2%. Central volume of distribution was estimated to be 10% smaller in female patients and clearance was found to be 17% lower in patients with HIV. Variability in absorption rate (90%) was completely interoccasional in nature, whereas in relative bioavailability, interoccasional variability (8.4%) was lower than interindividual variability (26%). Oral doses, given once daily according to dosing policies at the time, were sufficient to reach therapeutic concentrations in the majority of the studied population, regardless of eliminator phenotype. Simulations suggested that current treatment guidelines (5 mg kg(-1) ) may be suboptimal in fast eliminators with low body weight.
CONCLUSIONS:
A population pharmacokinetic model was developed to characterize the highly variable pharmacokinetics of isoniazid in a South African pulmonary tuberculosis patient population. Current treatment guidelines may lead to underexposure in rapid isoniazid eliminators.
AuthorsJustin J Wilkins, Grant Langdon, Helen McIlleron, Goonaseelan Pillai, Peter J Smith, Ulrika S H Simonsson
JournalBritish journal of clinical pharmacology (Br J Clin Pharmacol) Vol. 72 Issue 1 Pg. 51-62 (Jul 2011) ISSN: 1365-2125 [Electronic] England
PMID21320152 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society.
Chemical References
  • Antitubercular Agents
  • Isoniazid
Topics
  • Adult
  • Antitubercular Agents (pharmacokinetics)
  • Biological Availability
  • Black People
  • Clinical Trials as Topic
  • Female
  • Humans
  • Isoniazid (pharmacokinetics)
  • Male
  • Middle Aged
  • Models, Biological
  • South Africa
  • Tuberculosis, Pulmonary (metabolism)
  • White People
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: